ReviewBreast cancer research : BCR2005
Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt.
Review in Breast cancer research : BCR, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Prediction of individual response to anticancer therapy: historical and future perspectives.Cellular and molecular life sciences : CMLS · 2015Review
- The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine.Genome medicine · 2015Article
- Using logistic regression to improve the prognostic value of microarray gene expression data sets: application to early-stage squamous cell carcinoma of the lung and triple negative breast carcinoma.BMC medical genomics · 2014Article
- Challenges translating breast cancer gene signatures into the clinic.Nature reviews. Clinical oncology · 2011Article
- Stromal upregulation of lateral epithelial adhesions: gene expression analysis of signalling pathways in prostate epithelium.Journal of biomedical science · 2011Article
- Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer.Breast cancer research : BCR · 2008Review
- Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer.Proceedings of the National Academy of Sciences of the United States of America · 2006Article
- The impact of expression profiling on prognostic and predictive testing in breast cancer.Journal of clinical pathology · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review takes a sceptical view of the impact of breast cancer studies that have used microarrays to identify predictors of clinical outcome. In addition to discussing general pitfalls of microarray experiments, we also critically review the key breast cancer studies to highlight methodological problems in cohort selection, statistical analysis, validation of results and reporting of raw data. We conclude that the optimum use of microarrays in clinical studies requires further optimisation and standardisation of methodology and reporting, together with improvements in clinical study design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.